Regulatory T-cell therapy in the induction of transplant tolerance: The issue of subpopulations

Transplantation

Volumn 98, Issue 4, 2014, Pages 370-379

  Edozie, Francis C ^a,b   Nova Lamperti, Estefania A ^a,b   Povoleri, Giovanni A M ^a,b   Scottà, Cristiano ^a,b   John, Susan ^a,b   Lombardi, Giovanna ^a,b   Afzali, Behdad ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; FOXP3; Hemodialysis; Interleukin 17; Regulatory T cells; Subpopulation; Transplantation

Indexed keywords

CD161 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; LYMPHOCYTE SURFACE MARKER; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ACUTE GRAFT REJECTION; ADOPTIVE TRANSFER; BONE MARROW TRANSPLANTATION; CELL EXPANSION; CELL THERAPY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE PRODUCTION; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; TRANSPLANTATION TOLERANCE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL LINEAGE; CLASSIFICATION; CYTOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING; TRANSPLANTATION;

CELL DIFFERENTIATION; CELL LINEAGE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-17; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84907983401     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000243     Document Type: Review

References (125)

1. Mukherjee S, Mukherjee U. A comprehensive review of immunosup-pression used for liver transplantation. J Transplant 2009; 2009: 1.
2. Ito T, Hanabuchi S, Wang Y-H, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008; 28: 870.
3. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809.
4. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of in-terleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693.
5. Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319: 41.
6. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151.
7. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641.
8. Hall BM, Pearce NW, Gurley KE, et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990; 171: 141.
9. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005; 201: 1037.
10. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652.
11. Golshayan D, Jiang S, Tsang J, et al. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109: 827.
12. Zhang N, Schröppel B, Lal G, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009; 30: 458.
13. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
14. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
15. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcrip-tional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Investig 2008; 118: 2845.
16. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86: 1837.
17. Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Investig 2012; 122: 368.
18. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008; 86: 1370.
19. Zuber J, Grimbert P, Blancho G, et al. Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and attempt to reconcile discrepancies. Nephrol Dial Transplant 2013; 28: 1100.
20. Taflin C, Nochy D, Hill G, et al. Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function. Transplantation 2010; 89: 194.
21. Shultz LD, Brehm MA, Garcia-Martinez JV, et al. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012; 12: 786.
22. Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3: 83ra42.
23. Issa F, Hester J, Goto R, et al. Ex vivoYexpanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90: 1321.
24. Wu DC, Hester J, Nadig SN, et al. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation 2013; 96: 707.
25. Hester J, Schiopu A, Nadig SN, et al. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 2012; 12: 2008.
26. Trzonkowski P, Bieniaszewska M, Juvcicska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol 2009; 133: 22.
27. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061.
28. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921.
29. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Administration of CD4+CD25highCD127-regulatory T cells preserves A-cell function in type 1 diabetes in children. Diabetes Care 2012; 35: 1817.
30. Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr Opin Organ Transplant 2008; 13: 645.
31. Juvet SC, Whatcott AG, Bushell AR, et al. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant 2014 14: 750.
32. Scotta C, Esposito M, Fazekasova H, et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppres-sive qualities of human CD4(+)CD25(+)FOXP3(+) Tregulatory cell subpopulations. Haematologica 2013; 98: 1291.
33. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013; 14: 307.
34. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001; 193: F41.
35. Ziegler SF. FOXP3: of mice and men. Ann Rev Immunol 2006; 24: 209.
36. Povoleri GAM, Scotta C, Nova-Lamperti EA, et al. Thymic versus induced regulatory T cellsVwho regulates the regulators? Front Immunol 2013; 4: 169.
37. Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445: 931.
38. Sansom DM, Walker LSK. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006; 212: 131.
39. Ziegler SF. FOXP3: not just for regulatory T cells anymore. Eur J Immunol 2007; 37: 21.
40. Freeden-Jeffry von U, Vieira P, Lucian LA, et al. Lymphopenia in in-terleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181: 1519.
41. Jacobs SR, Michalek RD, Rathmell JC. IL-7 is essential for homeostatic control of T cell metabolism in vivo. J Immunol 2010; 184: 3461.
42. Rose T, Pillet A-H, Lavergne V, et al. Interleukin-7 compartmentalizes its receptor signaling complex to initiate CD4 T lymphocyte response. J Biol Chem 2010; 285: 14898.
43. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701.
44. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899.
45. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108: 4260.
46. Tresoldi E, Dell'Albani I, Stabilini A, et al. Stability of human rapamycin-expanded CD4+CD25+ Tregulatory cells. Haematologica 2011; 96: 1357.
47. Booth NJ, McQuaid AJ, Sobande T, et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J Immunol 2010; 184: 4317.
48. Afzali B, Mitchell PJ, Edozie FC, et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur J Immunol 2013; 43: 2043.
49. Kaczmarek E, Koziak K, Sévigny J, et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996; 271: 33116.
50. Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysi-ological significance. Purinergic Signal 2006; 2: 409.
51. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Ann Rev Immunol 2004; 22: 657.
52. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622.
53. Afzali B, Edozie FC, Fazekasova H, et al. Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation. Clin J Am Soc Nephrol 2013; 8: 1396.
54. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+ CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875.
55. Marie JC, Letterio JJ, Gavin M, et al. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201: 1061.
56. Coombes JL, Siddiqui KRR, Arancibia-Cárcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204: 1757.
57. Sun C-M, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007; 204: 1775.
58. Cobbold SP, Castejon R, Adams E, et al. Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172: 6003.
59. Curotto de Lafaille MA, Kutchukhidze N, Shen S, et al. Adaptive Foxp3+ regulatory T cell-dependent and-independent control of allergic inflammation. Immunity 2008; 29: 114.
60. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012; 209: 1713.
61. Weiss JM, Bilate AM, Gobert M, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 2012; 209: 1723.
62. Milpied P, Renand A, Bruneau J, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol 2009; 39: 1466.
63. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
64. Baron U, Floess S, Wieczorek G, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 2378.
65. Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008; 38: 1654.
66. Nagar M, Vernitsky H, Cohen Y, et al. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells. Int Immunol 2008; 20: 1041.
67. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21: 1105.
68. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98: 2736.
69. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271.
70. Kingsley CI, Karim M, Bushell AR, et al. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4-and IL-10-dependent immu-noregulation of alloresponses. J Immunol 2002; 168: 1080.
71. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789.
72. Huber S, Schramm C, Lehr HA, et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004; 173: 6526.
73. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566.
74. Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523.
75. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010; 327: 1098.
76. Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32.
77. Afzali B, Mitchell P, Mitchell P, et al. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol 2010; 159: 120.
78. Deknuydt F, Deknuydt F, Bioley G, et al. IL-1A and IL-2 convert human Treg into TH17 cells. Clin Immunol 2009; 131: 298.
79. Hori S. Regulatory T cell plasticity: beyond the controversies. Trends Immunol 2011; 32: 295.
80. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci 2009; 106: 1903.
81. Rubtsov YP, Niec RE, Josefowicz S, et al. Stability of the regulatory T cell lineage in vivo. Science 2010; 329: 1667.
82. Okamoto K, Sawa S, Nakashima T, et al. Pathogenic conversion of Foxp3(+) T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62.
83. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregsVrole in immune homeostasis and autoimmunity. Front Immunol 2013; 4: 232.
84. Koenen HJPM, Koenen HJPM, Smeets RL, et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340.
85. Pesenacker AM, Bending D, Ursu S, et al. CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood 2013; 121: 2647.
86. Hendrikx TK, van Gurp EAFJ, Mol WM, et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant 2009; 24: 1969.
87. Friedrich B, Janessa A, Schmieder R, et al. Acute effects of haemodialy-sis on pro-/anti-apoptotic genes in peripheral blood leukocytes. Cell Physiol Biochem 2008; 22: 423.
88. Meier P, Golshayan D, Blanc E, et al. Oxidized LDL modulates ap-optosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol 2009; 20: 1368.
89. Yoon J-W, Gollapudi S, Pahl MV, et al. NaBve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006; 70: 371.
90. Berglund D, Korsgren O, Lorant T, et al. Isolation, expansion and functional assessment of CD4+CD25+FoxP3+ regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation. Transpl Immunol 2012; 26: 27.
91. Chaturvedi V, Collison LW, Guy CS, et al. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661.
92. Gagliani N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013; 19: 739.
93. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213.
94. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233.
95. Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199: 1567.
96. Meiler F, Zumkehr J, Klunker S, et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205: 2887.
97. Inobe J-I, Slavin AJ, Komagata Y, et al. IL-4 is a differentiation factor for transforming growth factor-A secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur Jo Immunol 1998; 28: 2780.
98. Seder RA, Marth T, Sieve MC, et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J Immunol 1998; 160: 5719.
99. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207.
100. Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093.
101. Collison LW, Pillai MR, Chaturvedi V, et al. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35-and IL-10-dependent manner. J Immunol 2009; 182: 6121.
102. Gilliet M, Liu Y-J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195: 695.
103. Jiang S, Tugulea S, Pennesi G, et al. Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Hum Immunol 1998; 59: 690.
104. Li J, Liu Z, Jiang S, et al. Tsuppressor lymphocytes inhibit NF-kappa B-mediated transcription of CD86 gene in APC. J Immunol 1999; 163: 6386.
105. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739.
106. Ferlazzo G, Thomas D, Lin S-L, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455.
107. Chiesa Della M, Vitale M, Carlomagno S, et al. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur J Immunol 2003; 33: 1657.
108. Trivedi PP, Roberts PC, Wolf NA, et al. NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol 2005; 174: 4590.
109. Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: do "NK-reg cells" exist? Cell Mol Immunol 2006; 3: 241.
110. Hongo D, Tang X, Dutt S, et al. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood 2012; 119: 1581.
111. Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129.
112. Lemoine S, Morva A, Youinou P, et al. Human T cells induce their own regulation through activation of B cells. J Autoimmun 2011; 36: 228.
113. Chesneau M, Michel L, Degauque N, et al. Regulatory B cells and tolerance in transplantation: from animal models to human. Front Immunol 2013; 4: 497.
114. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005; 201: 1793.
115. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257.
116. Kleinewietfeld M, Puentes F, Borsellino G, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005; 105: 2877.
117. Schuler PJ, Harasymczuk M, Schilling B, et al. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011; 369: 59.
118. Sugimoto N, Oida T, Hirota K, et al. Foxp3-dependent and-independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 2006; 18: 1197.
119. Getnet D, Grosso JF, Goldberg MV, et al. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol 2010; 47: 1595.
120. Battaglia A, Buzzonetti A, Monego G, et al. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 2008; 123: 129.
121. Chen X, Subleski JJ, Hamano R, et al. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol 2010; 40: 1099.
122. Xiao X, Gong W, Demirci G, et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J Immunol 2012; 188: 892.
123. Stockis J, Colau D, Coulie PG, et al. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009; 39: 3315.
124. Wang R, Kozhaya L, Mercer F, et al. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci 2009; 106: 13439.
125. Edwards JP, Fujii H, Zhou AX, et al. Regulation of the expression of GARP/latent TGF-A1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J Immunol 2013; 190: 5506.